SMS Pharmaceuticals has reported a robust quarter driven by volume growth and operational efficiency, with revenue rising 21% year-on-year, EBITDA up 31%, and PAT jumping 29%. Nine-month PAT surged 42% YoY, reflecting strong execution across its diversified pharmaceutical portfolio.
The company’s EBITDA margin remained resilient above 20%, underpinned by operating leverage, while its ₹280 crore capacity expansion programme is on track for completion by FY27. SMS Pharma also achieved its full-year target of 10 DMF/CEP and dossier filings ahead of schedule, strengthening its future growth pipeline.
Commenting on the results, Executive Director P Vamsi Krishna said: "We concluded the quarter on a strong note with 29% PAT growth YoY. We continued to see strong demand across our diversified portfolio, with market share gains in key APIs driving revenue growth in a stable pricing environment.
"We further increased wallet share with existing customers while adding new customers in niche, high-value APIs. Our backward integration initiatives helped sustain margin resilience and further strengthened our position in regulated markets, particularly the US."
He added: "On the R&D front, we achieved our full-year target of 10 DMF/CEP and dossier filings ahead of schedule, reinforcing our future growth pipeline. We are targeting ~20 submissions over the next two years to sustain this momentum.
"Our ₹280 crore capacity expansion programme is progressing as planned and will support sustained growth and continued margin expansion over the next 2–3 years.
"For FY26, we remain on track to deliver ~20% revenue growth with EBITDA margins above 20%, supported by a diversified product portfolio, a strong product pipeline, and disciplined execution.”
SMS Pharma’s results highlight its ability to grow while maintaining margins and investing in future-ready capabilities, positioning the company for continued expansion in both domestic and regulated global markets.
